

Confirmatory Assignment

I/We, the undersigned

Inventor(s)

Jianguo CHEN, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Haixia LIU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Hong SHEN, a US citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Weixing ZHANG, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Wei ZHU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Employed by:

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

hereinafter INVENTOR(S), herewith declare that I / we contributed to
the invention(s) entitled:

Haloalkynyl compounds for the treatment of cancer

for which (a) priority application(s) was (were) filed with the

Patent Office

National Intellectual Property Administration,
People's Republic of China

as outlined below:

Case No.
37651-WO

Country
PCT

Filing Date
4 July 2022

Serial No.
PCT/CN2022/103694

INVENTOR(S) acknowledge(s) and confirm(s) that

Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203
China

hereinafter "EMPLOYER",
was assigned all my/our right, title, and interest in, to and deriving from the invention(s) disclosed in the
priority application(s) set forth above, prior to the filing date(s) of the priority application(s), including
any rights under international treaty or convention in and to aforementioned invention(s), and in and to

any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof in the United States of America. I/we are bound by the provisions provided in the "Confidentiality and IP Agreement" regarding "Service Invention" between me/us and EMPLOYER.

To the extent that any right, title, and interest of the INVENTOR(S) in, to, and deriving from patent application(s) or the invention(s) disclosed in the patent application(s) set forth above may not have been owned by EMPLOYER, INVENTOR(S) herewith assign(s) to EMPLOYER all of my/our worldwide right, title, and interest in, to, and deriving from the invention(s) and to the above priority application(s), including the right to claim priority, including any rights under international treaty or convention in and to aforementioned invention(s), and in and to any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof.

EMPLOYER, or its designee, shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name, or its designee's name, that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

INVENTOR(S)

Shanghai Aug 9. 2022
Place, Date

Jianguo CHEN
Jianguo CHEN

Shanghai, Aug 9, 2022
Place, Date

Haixia Liu
Haixia LIU

Shanghai, Aug 11, 2022
Place, Date

Hong SHEN
Hong SHEN

Shanghai Aug 9. 2022
Place, Date

Weixing Zhang
Weixing ZHANG

Shanghai Aug 9. 2022
Place, Date

Wei ZHU
Wei ZHU

EMPLOYER

Roche R&D Center (China) Ltd.

Shanghai Aug 11, 2022
Shanghai, Date

Yingxian ZHU
VP, Patent China

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



BR 757/2024

Dr. Nertz

Dr. Christoph Nertz, Notary Public

Case Record No. P37651-WO

ASSIGNMENT AGREEMENT

Roche R&D Center (China) Ltd. ("ASSIGNOR") a corporation duly organized under the laws of the People's Republic of China and having its principal place of business at Building 5, No. 720, Cailun Road, Shanghai, 201203, China

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.
37651-WO

Country
PCT

Filing Date
4 July 2022

Serial No.
PCT/CN2022/103694

entitled

Haloalkynyl compounds for the treatment of cancer

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case Record No. P37651-WO


This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche R&D Center (China) Ltd.

Shanghai, China
Place, Date

Aug. 11, 2022




Yingxian ZHU
VP, Patent China

ASSIGNEE

F. Hoffmann-La Roche AG

Basel, Switzerland,
Place, Date

August 15, 2022




Antonio Natoli
Holder of procuration



Petra Querfeld
Mandatory

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



BR 760/2024

Dr. Christoph Nertz, Notary Public

Confirmatory Assignment

I/We, the undersigned

Inventor(s)

Jianguo CHEN, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Haixia LIU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Hong SHEN, a US citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Weixing ZHANG, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Wei ZHU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Employed by:

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

hereinafter INVENTOR(S), herewith declare that I / we contributed to

the invention(s) entitled:

Haloalkynyl compounds for the treatment of cancer

for which (a) priority application(s) was (were) filed with the

Patent Office

National Intellectual Property Administration,
People's Republic of China

as outlined below:

Case No.
37651-WO-1

Country
PCT

Filing Date
11 October 2022

Serial No.
PCT/CN2022/124638

INVENTOR(S) acknowledge(s) and confirm(s) that

Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203
China

hereinafter "EMPLOYER",

was assigned all my/our right, title, and interest in, to and deriving from the invention(s) disclosed in the priority application(s) set forth above, prior to the filing date(s) of the priority application(s), including any rights under international treaty or convention in and to aforementioned invention(s), and in and to

any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof in the United States of America. I/we are bound by the provisions provided in the "Confidentiality and IP Agreement" regarding "Service Invention" between me/us and EMPLOYER.

To the extent that any right, title, and interest of the INVENTOR(S) in, to, and deriving from patent application(s) or the invention(s) disclosed in the patent application(s) set forth above may not have been owned by EMPLOYER, INVENTOR(S) herewith assign(s) to EMPLOYER all of my/our worldwide right, title, and interest in, to, and deriving from the invention(s) and to the above priority application(s), including the right to claim priority, including any rights under international treaty or convention in and to aforementioned invention(s), and in and to any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof.

EMPLOYER, or its designee, shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name, or its designee's name, that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

INVENTOR(S)

Shanghai, Dec 12, 2022
Place, Date

Jianguo CHEN
Jianguo CHEN

Shanghai, Dec 12, 2022
Place, Date

Haixia LIU
Haixia LIU

Shanghai, Jan 3, 2023
Place, Date

Hong SHEN
Hong SHEN

Shanghai, Dec 12, 2022
Place, Date

Weixing ZHANG
Weixing ZHANG

Shanghai, Dec 12, 2022
Place, Date

Wei ZHU
Wei ZHU

EMPLOYER

Roche R&D Center (China) Ltd.

Shanghai, Jan 3, 2023
Shanghai, Date

Yingxian ZHU
VP, Patent China

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



Dr. Christoph Nertz, Notary Public

BR 762/2024



Case Record No. P37651-WO-1

ASSIGNMENT AGREEMENT

Roche R&D Center (China) Ltd. ("ASSIGNOR") a corporation duly organized under the laws of the People's Republic of China and having its principal place of business at Building 5, No. 720, Cailun Road, Shanghai, 201203, China

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.
37651-WO-1

Country
PCT

Filing Date
11 October 2022

Serial No.
PCT/CN2022/124638

entitled

Haloalkynyl compounds for the treatment of cancer

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case Record No. P37651-WO-1


This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche R&D Center (China) Ltd.

Shanghai, China
Place, Date

Jan. 3, 2023




Yingxian ZHU
VP, Patent China

ASSIGNEE


F. Hoffmann-La Roche AG

Basel, Switzerland,
Place, Date

January 10th,
2023



Antonio Natoli
Holder of procuration



Petra Querfeld
Mandatory

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



Dr. Christoph Nertz

Dr. Christoph Nertz, Notary Public

BR 763/2024



Confirmatory Assignment

I/We, the undersigned

Inventor(s)

Jianguo CHEN, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Haixia LIU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Hong SHEN, a US citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Weixing ZHANG, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Wei ZHU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Employed by:

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

hereinafter INVENTOR(S), herewith declare that I / we contributed to

the invention(s) entitled:

Haloalkynyl compounds for the treatment of cancer

for which (a) priority application(s) was (were) filed with the

Patent Office

National Intellectual Property Administration,
People's Republic of China

as outlined below:

Case No.
37651-WO-2

Country
PCT

Filing Date
05 January 2023

Serial No.
PCT/CN2023/070765

INVENTOR(S) acknowledge(s) and confirm(s) that

Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203
China

hereinafter "EMPLOYER",
was assigned all my/our right, title, and interest in, to and deriving from the invention(s) disclosed in the
priority application(s) set forth above, prior to the filing date(s) of the priority application(s), including
any rights under international treaty or convention in and to aforementioned invention(s), and in and to
any and all applications filed and patents granted and issued therefor, or any continuation, division,

renewal, reissue or re-examination thereof, or substitutes thereof in the United States of America. I/we are bound by the provisions provided in the "Confidentiality and IP Agreement" regarding "Service Invention" between me/us and EMPLOYER.

To the extent that any right, title, and interest of the INVENTOR(S) in, to, and deriving from patent application(s) or the invention(s) disclosed in the patent application(s) set forth above may not have been owned by EMPLOYER, INVENTOR(S) herewith assign(s) to EMPLOYER all of my/our worldwide right, title, and interest in, to, and deriving from the invention(s) and to the above priority application(s), including the right to claim priority, including any rights under international treaty or convention in and to aforementioned invention(s), and in and to any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof.

EMPLOYER, or its designee, shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name, or its designee's name, that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

INVENTOR(S)

Shanghai Jan 13, 2023
Place, Date

Jianguo CHEN
Jianguo CHEN

Shanghai Jan 13, 2023
Place, Date

Haixia LIU
Haixia LIU

Shanghai Jan 31, 2023
Place, Date

Hong SHEN
Hong SHEN

Shanghai Jan 13, 2023
Place, Date

Weixing ZHANG
Weixing ZHANG

Shanghai Jan 13, 2023
Place, Date

Wei ZHU
Wei ZHU

EMPLOYER


Roche R&D Center (China) Ltd.

Shanghai Feb 1, 2023
Shanghai, Date

Yingxian ZHU
VP, Patent China

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



Dr. Christoph Nertz

Dr. Christoph Nertz, Notary Public

BR 765/2024



Case Record No. P37651-WO-2

ASSIGNMENT AGREEMENT

Roche R&D Center (China) Ltd. ("ASSIGNOR") a corporation duly organized under the laws of the People's Republic of China and having its principal place of business at Building 5, No. 720, Cailun Road, Shanghai, 201203, China

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.	Country	Filing Date	Serial No.
37651-WO-2	PCT	05 January 2023	PCT/CN2023/070765

entitled

Haloalkynyl compounds for the treatment of cancer

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case Record No. P37651-WO-2


This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche R&D Center (China) Ltd.

Shanghai, China
Place, Date

Feb. 1, 2023




Yingxian ZHU
VP, Patent China

ASSIGNEE


F. Hoffmann-La Roche AG

Basel, Switzerland,
Place, Date

February 6th,
2023



Antonio Natoli
Holder of procuration




Petra Querfeld
Mandatory

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



Dr. Christoph Nertz, Notary Public



BR 767/2024



Confirmatory Assignment

I/We, the undersigned

Inventor(s)

Jianguo CHEN, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Haixia LIU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Hong SHEN, a US citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Weixing ZHANG, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Wei ZHU, a Chinese citizen
c/o Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203, China

Employed by:

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

Roche R&D Center (China) Ltd

hereinafter INVENTOR(S), herewith declare that I / we contributed to
the invention(s) entitled:

Haloalkynyl compounds for the treatment of cancer

for which (a) priority application(s) was (were) filed with the

Chinese Patent Office

National Intellectual Property Administration,
People's Republic of China

as outlined below:

Case No.
37651-WO-3

Country
PCT

Filing Date
11 April 2023

Serial No.
PCT/CN2023/087633

INVENTOR(S) acknowledge(s) and confirm(s) that

Roche R&D Center (China) Ltd.
Building No. 5, Lane 720, Cailun Road
Shanghai, 201203
China

hereinafter "EMPLOYER",
was assigned all my/our right, title, and interest in, to and deriving from the invention(s) disclosed in the
priority application(s) set forth above, prior to the filing date(s) of the priority application(s), including
any rights under international treaty or convention in and to aforementioned invention(s), and in and to
any and all applications filed and patents granted and issued therefor, or any continuation, division,

renewal, reissue or re-examination thereof, or substitutes thereof in the United States of America. I/we are bound by the provisions provided in the "Confidentiality and IP Agreement" regarding "Service Invention" between me/us and EMPLOYER.

To the extent that any right, title, and interest of the INVENTOR(S) in, to, and deriving from patent application(s) or the invention(s) disclosed in the patent application(s) set forth above may not have been owned by EMPLOYER, INVENTOR(S) herewith assign(s) to EMPLOYER all of my/our worldwide right, title, and interest in, to, and deriving from the invention(s) and to the above priority application(s), including the right to claim priority, including any rights under international treaty or convention in and to aforementioned invention(s), and in and to any and all applications filed and patents granted and issued therefor, or any continuation, division, renewal, reissue or re-examination thereof, or substitutes thereof.

EMPLOYER, or its designee, shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name, or its designee's name, that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

INVENTOR(S)

Shanghai Apr 14, 2023
Place, Date

Jianguo CHEN
Jianguo CHEN

Shanghai Apr 14, 2023
Place, Date

Haixia LIU
Haixia LIU

Shanghai, Apr. 28, 2023
Place, Date

Hong SHEN
Hong SHEN

Shanghai April 4, 2024
Place, Date

Weixing ZHANG
Weixing ZHANG

Shanghai 12.14. 2023
Place, Date

Wei ZHU
Wei ZHU

EMPLOYER


Roche R&D Center (China) Ltd.

Shanghai May 16, 2023
Place, Date

Yingxian ZHU
VP, Patent China

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



McGin

Dr. Christoph Nertz, Notary Public

BR 769/2024



For true photocopy

Case Record No. P37651-WO-3

ASSIGNMENT AGREEMENT

Roche R&D Center (China) Ltd. ("ASSIGNOR") a corporation duly organized under the laws of the People's Republic of China and having its principal place of business at Building 5, No. 720, Cailun Road, Shanghai, 201203, China

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.
37651-WO-3

Country
PCT

Filing Date
11 April 2023

Serial No.
PCT/CN2023/087633

entitled

Haloalkynyl compounds for the treatment of cancer

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case Record No. P37651-WO-3

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche R&D Center (China) Ltd.

Shanghai, China
Place, Date

May 16, 2023

Yingxian ZHU

VP, Patent China

ASSIGNEE

F. Hoffmann-La Roche AG

Basel, Switzerland,
Place, Date

June 14, 2023

Antonio Natoli

Holder of procuration

Petra Querfeld

Mandatory

For true photocopy:

B a s e l (Switzerland), 6th (sixth) day of November 2024 (two thousand and twenty-four).



Dr. Christoph Nertz

Dr. Christoph Nertz, Notary Public

BR 771/2024